Leysen J E
Johnson & Johnson Pharmaceuticals, Business Development, Scientific Licensing, B-2340 Beerse, Belgium.
Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):11-26. doi: 10.2174/1568007043482598.
5-HT(2) receptors are G-protein coupled receptors that currently comprise three subtypes: 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. The subtypes are related in their molecular structure, amino acid sequence and signaling properties. 5-HT(2A) and 5-HT(2C) receptors have a widespread distribution and function in the central nervous system. 5-HT(2A)and 5-HT(2C) receptor antagonism is a property of certain antipsychotic and antidepressant drugs. 5-HT(2B) receptors have a restricted expression in the central nervous system. They have an important role in embryogenesis and in the periphery. In this article, selected aspects of 5-HT(2) receptor research are reviewed for each subtype under three main headings : (i) genes, protein structure and receptor signaling; (ii) receptor localization with emphasis on the CNS and (iii) compounds. The general discussion reflects on the reasons for the limited success in the clinic of 5-HT(2) receptor subtype selective drugs.
5-羟色胺(5-HT)(2) 受体是G蛋白偶联受体,目前包括三种亚型:5-HT(2A)、5-HT(2B) 和5-HT(2C) 受体。这些亚型在分子结构、氨基酸序列和信号特性方面相关。5-HT(2A) 和5-HT(2C) 受体在中枢神经系统中广泛分布并发挥作用。5-HT(2A) 和5-HT(2C) 受体拮抗作用是某些抗精神病药和抗抑郁药的特性。5-HT(2B) 受体在中枢神经系统中的表达受限。它们在胚胎发生和外周组织中起重要作用。在本文中,5-HT(2) 受体研究的选定方面在三个主要标题下针对每个亚型进行了综述:(i) 基因、蛋白质结构和受体信号传导;(ii) 受体定位,重点是中枢神经系统;(iii) 化合物。一般性讨论反映了5-HT(2) 受体亚型选择性药物在临床上取得有限成功的原因。